Key Highlights

  • Eli Lilly (NYSE:LLY) posted third quarter Revenue of USD 24.4 billion, a 39% jump, with Volume up 53% while realized prices fell 15%.
  • Mounjaro sales grew 65% to USD 10.7 billion and Zepbound climbed 49% to USD 5.4 billion, and Foundayo added USD 184 million.
  • Full year 2026 revenue guidance now sits at USD 91 billion to USD 92 billion, up from USD 85 billion to USD 87 billion.
  • In the latest session the shares were quoted at USD 1,415.55, down 1.13% on the day and within roughly 4% of their 52-week high.

Incretin Demand Fuels Another Strong Quarter

Eli Lilly published its third quarter 2026 numbers on October 29, marking another period of remarkable expansion. Revenue climbed 39% to USD 24.4 billion from USD 17.6 billion. Worldwide volume rose 53% while realized prices were 15% lower. In the United States, revenue increased 34% to USD 15.1 billion, and sales outside the country jumped 47% to USD 9.3 billion, with the lower pricing there mostly reflecting Mounjaro's addition to China's national reimbursement list. Mounjaro and Zepbound together brought in about two thirds of total revenue, at USD 10.7 billion and USD 5.4 billion respectively. Foundayo, the oral medicine formerly called orforglipron, generated USD 184 million during its first full quarter, compared with USD 98 million in the second quarter. Total revenue also contained roughly USD 900 million of one-time benefits, including USD 410 million of Jardiance milestones that will not come back. Reported EPS increased 16% to USD 7.22, while non-GAAP EPS was USD 7.48. Both measures carried a USD 4.57 per share hit from acquired research charges tied mainly to the AtaiBeckley and Curevo deals.

A Third Guidance Increase and Regulatory Progress

The company lifted its revenue outlook for the third time this year, now at USD 91 billion to USD 92 billion versus the earlier USD 85 billion to USD 87 billion. Non-GAAP EPS guidance sits at USD 35.00 to USD 36.00, since a higher operating midpoint was outweighed by the acquired research charges taken during the quarter. The performance Margin forecast moved up to 52.0% to 52.5% from 49.0% to 50.5%. Gross margin came in at 83.9% of revenue, a one point improvement. Chair and chief executive David A. Ricks noted that the Business beat earlier expectations and that this allowed the full year outlook to rise. Several U.S. approvals arrived during the period, including Mounjaro for cardiovascular risk reduction in adults with type 2 diabetes, Onswik, a once weekly insulin, Inluriyo for a form of advanced breast cancer, and a broader label for Jaypirca in previously untreated chronic lymphocytic leukemia. A head to head trial of retatrutide against a competing treatment also delivered better blood sugar and weight outcomes, and the company intends to file for approval of retatrutide in early 2027.

A Busy November for Foundayo and Supply

Several developments since the results have kept the stock in focus. On November 6 Lilly agreed with Hims and Hers to sell Foundayo starting at USD 149 a month and Zepbound starting at USD 299 a month on a self-pay basis, and the telehealth provider committed to stop selling compounded versions of Lilly's treatments. On November 9 Foundayo hit its primary endpoint in an obstructive sleep apnea study, and a regulatory filing is planned before the end of 2026. On November 12 the company broke ground on a USD 3.5 billion injectables Facility in Pennsylvania's Lehigh Valley, its tenth new U.S. site since 2020. At ObesityWeek, held November 14 to 17, Lilly shared fresh findings on Zepbound, Foundayo, retatrutide and EloraTZP, including up to 23.3% weight loss at 48 weeks for EloraTZP in a Phase 2 trial. The company also declared a fourth quarter Dividend of USD 1.73 per share, payable December 10, and set an Innovation Day for December.

Where Things Stand

Eli Lilly sits near its 52-week high as volume growth, a third guidance increase and a steady stream of Foundayo news outweigh lower pricing. For Canadian investors, the next items to track are the one-time revenue items and the December Innovation Day.